The DOI matches its Crossref record; 189 of the 189 references it cites were found in a registry or an index.
Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases
Open accessAbstract
Interleukin-1 (IL-1) is a highly active pro-inflammatory cytokine that lowers pain thresholds and damages tissues. Monotherapy blocking IL-1 activity in autoinflammatory syndromes results in a rapid and sustained reduction in disease severity, including reversal of inflammation-mediated loss of sight, hearing and organ function. This approach can therefore be effective in treating common conditions such as post-infarction heart failure, and trials targeting a broad spectrum of new indications are underway. So far, three IL-1-targeted agents have been approved: the IL-1 receptor antagonist anakinra, the soluble decoy receptor rilonacept and the neutralizing monoclonal anti-IL-1β antibody canakinumab. In addition, a monoclonal antibody directed against the IL-1 receptor and a neutralizing anti-IL-1α antibody are in clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biologic basis for interleukin-1 in disease.
Dinarello, C. (1996) · Blood · doi:10.1182/blood.v87.6.2095.bloodjournal8762095 · Cited by 4,344
Self-citationNLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
Duewell, P., Kono, H., Rayner, K. J., Sirois, C. M., Vladimer, G., Bauernfeind, F. G., Abela, G. S., Franchi, L., Nuñez, G., Schnurr, M., et al. (2010) · Nature · doi:10.1038/nature08938 · Cited by 4,026
Type 2 diabetes as an inflammatory disease
Donath, M. Y., & Shoelson, S. E. (2011) · Nature Reviews Immunology · doi:10.1038/nri2925 · Cited by 3,737
Role of proinflammatory cytokines in the pathophysiology of osteoarthritis
Kapoor, M., Martel-Pelletier, J., Lajeunesse, D., Pelletier, J.-P., & Fahmi, H. (2011) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2010.196 · Cited by 2,778
The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance
Vandanmagsar, B., Youm, Y.-H., Ravussin, A., Galgani, J. E., Stadler, K., Mynatt, R. L., Ravussin, E., Stephens, J. M., & Dixit, V. D. (2011) · Nature Medicine · doi:10.1038/nm.2279 · Cited by 2,655
Ferrara, J. L., Levine, J. E., Reddy, P., & Holler, E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60237-3 · Cited by 2,464
The Inflammasomes: Guardians of the Body
Martinon, F., Mayor, A., & Tschopp, J. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132715 · Cited by 2,436
Interleukin-1 in the pathogenesis and treatment of inflammatory diseases
Dinarello, C. A. (2011) · Blood · doi:10.1182/blood-2010-07-273417 · Cited by 2,248
Self-citationInflammation in Atherosclerosis
Libby, P., Ridker, P. M., & Hansson, G. K. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.09.009 · Cited by 2,228
Interleukin-1-receptor antagonist in type 2 diabetes mellitus
Larsen, C. M., Faulenbach, M., Vaag, A., Vølund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T., & Donath, M. Y. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065213 · Cited by 1,798
Cited by
Items 101–117 of 117
Cohen, I., Rider, P., Vornov, E., Tomas, M., Tudor, C., Wegner, M., Brondani, L., Freudenberg, M., Mittler, G., Ferrando-May, E., et al. (2015) · Scientific Reports · doi:10.1038/srep14756 · Cited by 98
Self-citationÅgerstam, H., Hansen, N., von Palffy, S., Sandén, C., Reckzeh, K., Karlsson, C., Lilljebjörn, H., Landberg, N., Askmyr, M., Högberg, C., et al. (2016) · Blood · doi:10.1182/blood-2015-11-679985 · Cited by 98
Weisser, M., Demel, U. M., Stein, S., Chen-Wichmann, L., Touzot, F., Santilli, G., Sujer, S., Brendel, C., Siler, U., Cavazzana, M., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.11.028 · Cited by 77
Ubertini, V, Norelli, G., D'Arcangelo, D., Gurtner, A., Cesareo, E., Baldari, S., Gentileschi, M. P., Piaggio, G., Nisticò, P., Soddu, S., et al. (2015) · Oncogene · doi:10.1038/onc.2014.191 · Cited by 75
Targeting aging and age-related diseases with vaccines
Wu, R., Sun, F., Zhang, W., Ren, J., & Liu, G.-H. (2024) · Nature Aging · doi:10.1038/s43587-024-00597-0 · Cited by 66
Bjurstrom, M. F., Giron, S. E., & Griffis, C. A. (2016) · Pain Practice · doi:10.1111/papr.12252 · Cited by 62
Galactosaminogalactan of Aspergillus fumigatus, a bioactive fungal polymer
Briard, B., Muszkieta, L., Latgé, J.-P., & Fontaine, T. (2016) · Mycologia · doi:10.3852/15-312 · Cited by 61
Treating Pulmonary Silicosis by Blocking Interleukin 1
Cavalli, G., Fallanca, F., Dinarello, C. A., & Dagna, L. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201412-2150le · Cited by 56
Self-citationInterleukin-1α and brain inflammation
Brough, D., & Denes, A. (2015) · IUBMB Life · doi:10.1002/iub.1377 · Cited by 54
The Activation of IL-1-Induced Enhancers Depends on TAK1 Kinase Activity and NF-κB p65
Jurida, L., Soelch, J., Bartkuhn, M., Handschick, K., Müller, H., Newel, D., Weber, A., Dittrich-Breiholz, O., Schneider, H., Bhuju, S., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.01.001 · Cited by 51
Billon, C., Canaple, L., Fleury, S., Deloire, A., Beylot, M., Dombrowicz, D., del Carmine, P., Samarut, J., & Gauthier, K. (2014) · Endocrinology · doi:10.1210/en.2014-1098 · Cited by 45
“The production of IL-1 is recognized as an early step of inflammation already targeted in human inflammatory diseases by Anakinra, and for which clinical trials are underway for metabolic diseases such as diabetes or atherosclerosis (40).”
BackgroundZolondick, A. A., Gaudino, G., Xue, J., Pass, H. I., Carbone, M., & Yang, H. (2021) · Precision Cancer Medicine · doi:10.21037/pcm-21-12 · Cited by 41
Uchino, Y., Woodward, A. M., Mauris, J., Peterson, K., Verma, P., Nilsson, U. J., Rajaiya, J., & Argüeso, P. (2018) · Immunology · doi:10.1111/imm.12899 · Cited by 31
Impact of mast cells in fibromyalgia and low‐grade chronic inflammation: Can IL‐37 play a role?
Conti, P., Gallenga, C. E., Caraffa, A., Ronconi, G., & Kritas, S. K. (2020) · Dermatologic Therapy · doi:10.1111/dth.13191 · Cited by 29
Gressler, M., Heddergott, C., N'Go, I. C., Renga, G., Oikonomou, V., Moretti, S., Coddeville, B., Gaifem, J., Silvestre, R., Romani, L., et al. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00365 · Cited by 27
A review of canakinumab and its therapeutic potential for non-small cell lung cancer
Schenk, K. M., Reuss, J. E., Choquette, K., & Spira, A. I. (2019) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000832 · Cited by 22
Katifelis, H., Filidou, E., Psaraki, A., Yakoub, F., Roubelakis, M. G., Tarapatzi, G., Vradelis, S., Bamias, G., Kolios, G., & Gazouli, M. (2022) · Biomedicines · doi:10.3390/biomedicines10102357 · Cited by 15
“In addition, pharmaceutical agents that target IL-1β have been already tested (including anti-IL-1β antibodies) [41].”
Background
Metadata
- Authors
- Dinarello, C. A., Simon, A., & van der Meer, J. W. M.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2012-08
- Volume
- 11
- Issue
- 8
- Pages
- 633-652
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2108373994
- Cited by
- 1,768
- References
- 189
- FWCI
- 7.02
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.